Medical Device

Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC

- Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy systems will be incorporated into Abbott's existing endovascular product portfolio . Financial terms were not disclosed.

"The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott's ability to provide one-of-a-kind endovascular therapy solutions to improve patient care," said Julie Tyler , senior vice president of Abbott's vascular business. "Walk Vascular's technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care."

Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO (All In One) Peripheral Thrombectomy System are unique aspiration systems for the removal of intravascular clots, known as thrombus, that can reduce blood flow and lead to serious complications for patients. The innovative JETi systems are designed to break-up and remove clots from the peripheral vascular system while reducing the risk of dislodged clots. The systems are backed by real-world clinical experiences, and Walk is currently enrolling up to 250 patients in the United States and Europe in the JETi Registry.

Both the JETi Peripheral Thrombectomy Systems have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Cision View original content: https://www.prnewswire.com/news-releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc-301368214.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Knight to Present at the Jefferies 2023 Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2023 Healthcare Conference on Friday, June 9, 2023 at 9:00 AM ET in New York City. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic names Ken Washington new Chief Technology and Innovation Officer

Medtronic plc (NYSE:MDT) today announced that Ken Washington Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer. In this newly created role, Dr. Washington will leverage his extensive experience leading technology development and execution across industries including robotics, consumer products, automotive, and space, to accelerate innovation-driven growth in service of the company's mission to alleviate pain, restore health and extend life. Dr. Washington will also become a member of the Medtronic Executive Committee.

"This new leadership role will help Medtronic to harness the innovative spirit of our founders and ensure we are capitalizing on our scientific and technological knowledge to invent, innovate and disrupt the healthcare technology market of the future," said Geoff Martha, chairman and CEO, Medtronic. "Dr. Washington will help Medtronic expand use of our technology platforms across our portfolio – including robotics, sensors, implantables and AI – improving our returns on investments in innovation and expanding our technological competitive advantage to drive durable growth."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease

Cover Your Bases Campaign Kicks Off Oral Health Month with ARESTIN (minocycline HCI) Patient Ambassador Alex Rodriguez

Bausch Health Companies Inc. (NYSETSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover Your Bases campaign includes educational content about the disease and encourages patients to talk to their dentist about comprehensive treatment options. The campaign launch is timed to Oral Health Month recognized throughout June and features Alex as a patient ambassador.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
laptop, stethoscope, smartphone, pen and eyeglasses on desk

How to Invest in Medical Devices (Updated 2023)

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.

This industry covers a wide range of health and medical instruments used in the treatment, mitigation, diagnosis and prevention of diseases and physical conditions, and it continues to develop rapidly.

Examples of medical devices include neurostimulation devices, surgical implants, ultrasound imaging devices and robotic medical technology, along with insulin pumps and insulin pens for diabetes. Just as pharmaceutical companies seek to serve unmet needs, medical device companies do the same via innovative technologies.

Keep reading...Show less

Medtronic to acquire wearable insulin patch maker EOFlow

Acquisition will expand company's ability to serve more people living with diabetes around the world within one seamless Medtronic ecosystem of support

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd. (KOSDAQ: 294090), manufacturer of the EOPatch® device — a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes, no matter where they are in their treatment journey or preference for how they want their insulin delivered.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase

Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company

Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2023, which ended April 28, 2023 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×